Related coverage linked through entity extraction aliases.
Aug 02, 2026
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Jul 23, 2026
Tortugas Neuroscience and Korsana Biosciences emerged with significant funding to advance clinical-stage pipelines targeting neurological and neurodegenerative diseases. Tortugas raised $106 million, while Korsana secured $175 million to develop therapies for conditions including Alzheimer's, schizophrenia, and epilepsy.
Jun 14, 2026
Three biotech companies announce significant funding: Korsana Biosciences secures $175 million for neurodegenerative therapies, Kos Biotechnology Partners closes a $123 million life sciences fund, and ParcelBio launches with $13 million to advance mRNA medicines.
Mar 06, 2026
Two gene therapies for inherited eye diseases have progressed to clinical trials, with the FDA clearing Sanaregen's SVT-001 for Familial Drusen and SpliceBio treating its first patient in a Stargardt disease trial in Oxford.
Feb 19, 2026
Korsana Biosciences launched from stealth with $175 million in funding to advance KRSA-028, a monoclonal antibody targeting amyloid beta plaques in Alzheimer's disease using a blood-brain barrier shuttle technology.
